<DOC>
	<DOCNO>NCT00239278</DOCNO>
	<brief_summary>The purpose study determine whether budesonide+formoterol combination effective treatment exacerbation COPD main emphasis investigate effect inflammation secondary emphasis clinical efficacy</brief_summary>
	<brief_title>Budesonide / Formoterol Treatment Exacerbations COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>smokinginduced COPD accord ATS criterion FEV1 &lt; 85 % predict enrolment &lt; 70 % predict &gt; 0.7 Liter Exacerbation FEV1/IVC ratio &lt; 88 % predict men &lt; 89 % woman history asthma know hypersensitivity study drug serious concomitant disease pregnancy lactate abnormal Chest Xray blood gas</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>